Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an antibody slow Alzheimer's? a new trial seeks answers

NCT ID NCT04867616

Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This phase 2 trial is testing whether an experimental antibody called bepranemab can slow the progression of Alzheimer's disease in people with early-stage symptoms. Participants receive either bepranemab or a placebo by intravenous infusion over 80 weeks. The study measures changes in memory, thinking, and daily function to see if the drug can preserve cognitive abilities.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental antibody called bepranemab
What this could lead to
If it works, this could point toward a treatment that slows memory loss and cognitive decline in early Alzheimer's disease.
What could go wrong
This is a mid-stage trial, so the drug may not prove effective or could cause side effects. Alzheimer's is complex, and many experimental treatments have failed before.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

466 people

The number who actually took part.

Started

Jun 2021

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 50 to 80 years of age * Diagnosis of prodromal/mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD according to National Institute of Aging-Alzheimer's Association (NIA-AA) * A global Clinical Dementia Rating (CDR) score of 0.5 to 1.0 and CDR-Memory Box (CDRMB) score ≥0.5 at Screening and Baseline * Score of ≤85 for the delayed recall domain of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at Screening * Mini-Mental State Examination (MMSE) score ≥20 at Screening * Participant has an identified informant that has and will maintain sufficient contact (minimum of 5 hours per week) with the participant to be able to provide accurate information on the participant's cognitive, functional, and emotional states and of the participant's personal care * At least 6 years of formal education after the age of 5 or work experience to exclude mental deficits other than prodromal or mild AD dementia * Evidence of cerebral Aβ accumulation by either positive amyloid assessment by either positron emission tomography (PET) scan or cerebrospinal fluid pTau181/Aβ1-42 ratio assessment Exclusion Criteria: * Any evidence of a condition that may affect cognition other than AD * Contraindications to PET imaging * Inability to tolerate or contraindication to magnetic resonance imaging * Any serious medical condition or abnormality that in the opinion of the investigator would preclude safe participation in and completion of the study or interfere with study assessments and/or study interpretation * Alcohol or drug abuse within 2 years of screening * Use of any experimental therapy within the past 6 months (or 5 half lives) prior to screening * Previous treatment with medication intended to treat a neurodegenerative disorder (other than AD) within 1 year of screening * Chronic daily treatment with atypical antipsychotics, opiates or opioids, benzodiazepines, barbiturates, hypnotics, or any medication with clinically significant centrally acting antihistamine or anticholinergic activitiy * Received treatment with monoclonal antibodies (mAbs), cytokines, immunoglobulins, or other blood products within 3 months or 5 half-lives (whichever is longer) prior to first dosing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer's disease

Contacts and locations

Locations

  • Ah0003 40002

    Leuven, Belgium

  • Ah0003 40028

    Berlin, Germany

  • Ah0003 40049

    Seville, Spain

  • Ah0003 40105

    Córdoba, Spain

  • Ah0003 40123

    Brussels, Belgium

  • Ah0003 40129

    Bordeaux, France

  • Ah0003 40159

    Barcelona, Spain

  • Ah0003 40160

    Barcelona, Spain

  • Ah0003 40201

    Rennes, France

  • Ah0003 40230

    Valencia, Spain

  • Ah0003 40267

    Barcelona, Spain

  • Ah0003 40280

    Sant Cugat del Vallès, Spain

  • Ah0003 40352

    Pamplona, Spain

  • Ah0003 40371

    Monza, Italy

  • Ah0003 40430

    Munich, Germany

  • Ah0003 40438

    Roma, Italy

  • Ah0003 40449

    's-Hertogenbosch, Netherlands

  • Ah0003 40450

    Amsterdam, Netherlands

  • Ah0003 40453

    Terrassa, Spain

  • Ah0003 40493

    Marseille, France

  • Ah0003 40540

    Madrid, Spain

  • Ah0003 40575

    Brussels, Belgium

  • Ah0003 40576

    Kortrijk, Belgium

  • Ah0003 40578

    Paris, France

  • Ah0003 40579

    Villeurbanne, France

  • Ah0003 40580

    Bron, France

  • Ah0003 40581

    Toulouse, France

  • Ah0003 40596

    Rome, Italy

  • Ah0003 40597

    Pavia, Italy

  • Ah0003 40598

    Rome, Italy

  • Ah0003 40600

    Parma, Italy

  • Ah0003 40601

    Zwolle, Netherlands

  • Ah0003 40602

    Warsaw, Poland

  • Ah0003 40603

    Bialystok, Poland

  • Ah0003 40604

    Warsaw, Poland

  • Ah0003 40605

    Katowice, Poland

  • Ah0003 40606

    Bydgoszcz, Poland

  • Ah0003 40607

    Warsaw, Poland

  • Ah0003 40608

    Szczecin, Poland

  • Ah0003 40609

    Katowice, Poland

  • Ah0003 40611

    Wroclaw, Poland

  • Ah0003 40612

    Barcelona, Spain

  • Ah0003 40613

    Valencia, Spain

  • Ah0003 40614

    Donostia / San Sebastian, Spain

  • Ah0003 40615

    Madrid, Spain

  • Ah0003 40616

    Zaragoza, Spain

  • Ah0003 40618

    London, United Kingdom

  • Ah0003 40619

    Bristol, United Kingdom

  • Ah0003 40621

    London, United Kingdom

  • Ah0003 40622

    Guildford, United Kingdom

  • Ah0003 40623

    Plymouth, United Kingdom

  • Ah0003 40635

    Nantes, France

  • Ah0003 40638

    Ścinawa, Poland

  • Ah0003 40662

    Birmingham, United Kingdom

  • Ah0003 40691

    Winchester, United Kingdom

  • Ah0003 40774

    Katowice, Poland

  • Ah0003 50045

    Toronto, Canada

  • Ah0003 50291

    Toronto, Canada

  • Ah0003 50380

    Houston, Texas, 77054, United States

  • Ah0003 50420

    Neptune City, New Jersey, 07753, United States

  • Ah0003 50421

    Stamford, Connecticut, 06905, United States

  • Ah0003 50422

    New Haven, Connecticut, 06510, United States

  • Ah0003 50423

    East Providence, Rhode Island, 02914, United States

  • Ah0003 50424

    Fairfax, Virginia, 22031, United States

  • Ah0003 50426

    Maitland, Florida, 32751, United States

  • Ah0003 50427

    Miami, Florida, 33125, United States

  • Ah0003 50428

    Fresno, California, 93710, United States

  • Ah0003 50429

    Fort Myers, Florida, 33912, United States

  • Ah0003 50430

    Delray Beach, Florida, 33445, United States

  • Ah0003 50431

    Fullerton, California, 92835, United States

  • Ah0003 50432

    Norfolk, Virginia, 23507, United States

  • Ah0003 50434

    Santa Ana, California, 92705, United States

  • Ah0003 50435

    Boca Raton, Florida, 33487, United States

  • Ah0003 50436

    Hialeah, Florida, 33016, United States

  • Ah0003 50438

    Pensacola, Florida, 32502, United States

  • Ah0003 50440

    Bellevue, Washington, 98007, United States

  • Ah0003 50442

    Irvine, California, 92614, United States

  • Ah0003 50444

    West Palm Beach, Florida, 33407, United States

  • Ah0003 50445

    Braintree, Massachusetts, 02184, United States

  • Ah0003 50446

    Westchester, Florida, 33155, United States

  • Ah0003 50447

    San Diego, California, 92123, United States

  • Ah0003 50448

    Saint Paul, Minnesota, 55130, United States

  • Ah0003 50449

    Aventura, Florida, 33180, United States

  • Ah0003 50450

    Palo Alto, California, 94303, United States

  • Ah0003 50451

    Cincinnati, Ohio, 45219, United States

  • Ah0003 50452

    Pasadena, California, 91106, United States

  • Ah0003 50453

    Newton, Massachusetts, 02459, United States

  • Ah0003 50454

    Tampa, Florida, 33613, United States

  • Ah0003 50455

    Cordova, Tennessee, 38018, United States

  • Ah0003 50457

    Port Orange, Florida, 32127, United States

  • Ah0003 50458

    Long Beach, California, 90807, United States

  • Ah0003 50461

    Ottawa, Canada

  • Ah0003 50462

    Toronto, Canada

  • Ah0003 50463

    Kelowna, Canada

  • Ah0003 50464

    Ocoee, Florida, 34761, United States

  • Ah0003 50465

    Atlantis, Florida, 33462, United States

  • Ah0003 50467

    New Haven, Connecticut, 06510, United States

  • Ah0003 50476

    West Palm Beach, Florida, 33409, United States

  • Ah0003 50478

    Naples, Florida, 34105, United States

  • Ah0003 50479

    Decatur, Georgia, 30033, United States

  • Ah0003 50520

    Québec, Canada

  • Ah0003 50522

    West Vancouver, Canada

  • Ah0003 50623

    Pensacola, Florida, 32503, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.